Soluble CD146 and Proteinuria in Chronic Renal Disease (CPinMRC)

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Completed

Conditions: Chronic Renal Failure

Treatments: Biological: Recurring blood sample

Study type: Interventional

Funder types: Other

Identifiers

NCT03341949

2017-12

ID RCB (Other Identifier)

Details and patient eligibility

About

Chronic renal disease (CKD) is defined as a decrease in glomerular filtration rate (GFR) and / or proteinuria or albuminuria (a protein present in urine). Albuminuria is considered a marker of endothelial dysfunction. Proteinuria and / or albuminuria are recognized as cardiovascular risk factors in both diabetic and non-diabetic populations, independently of GFR. It is also a marker of progression of kidney disease. cluster of differentiation 146 (CD146) is an endothelial adhesion molecule with preferential localization in the junction. Soluble CD146 (or CD146s). CD146s is a biomarker of endothelial dysfunction that is easy to assay. The increase in CD146 levels was described during the MRC, especially in diabetic patients with significant proteinuria. In two independent cohorts of patients with CDR, CD146s did not correlate with creatinine or GFR but appeared to correlate with proteinuria.

The aim of our study is to determine whether the blood concentration of CD146s is correlated with proteinuria independently of GFR. For this purpose, we propose this study in the kidney nephrology and transplantation center of Conception Hospital, with the objective of highlighting the link between proteinuria and serum CD146 levels in patients with CKD, whatever their renal function and / or underlying pathology. 205 patients will be included over two years with dosing of CD146s and proteinuria at the same time. These 205 patients will be recruited at each stage of the CKD (41 in each arm). CD146s could be a new biomarker predicting the risk of renal function impairment or cardiovascular risk independent of renal function.

Enrollment: 204 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult subject aged 18 years or over
• Subject capable of giving informed consent
• Patient with chronic kidney disease (stage 1 to 5 CKD regardless of etiology)

Exclusion criteria

• Pregnant or lactating woman
• Person deprived of liberty or hospitalized without consent
• Major under legal protection or unable to express his consent
• Refusal of the patient
• Patient with a history of kidney transplantation
• Evolutionary cancer

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

204 participants in 1 patient group

Patient with chronic kidney disease

Experimental group

Description:

Determination of the Cluster of Differentiation 146 (CD146)

Treatment:

Biological: Recurring blood sample